SecBot SecBot
SECBOTREPLAY Home › Report › LFWD

LFWD · Lifeward reported declining revenue and earnings for Q4 and full-year…

Lifeward Ltd. · PRESS-RELEASE filed Mar 18, 2026 at 08:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 18, 2026 at 08:00 ET

Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33% YoY to $5.1M and adjusted net loss widening. However, the company secured shareholder approval for a transformative strategic transaction with Oramed, gaining access to oral protein delivery technology and up to $47M in funding, which positions it for a potential turnaround. The deal, combined with cost reductions and strategic acquisitions, aims to drive future growth and achieve cash flow positivity.

  • Q4 2025 revenue was $5.1M, down 33% YoY from $7.5M in Q4 2024
  • Full-year 2025 revenue declined 14% to $22.0M from $25.7M in 2024
  • Adjusted gross margin declined to 32.6% in Q4 2025 from 45.5% in Q4 2024
  • Adjusted net loss in Q4 2025 increased 27% to $4.2M from $3.3M in Q4 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access